Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 51M | 9.6% |
| Gross Profit | 39M | 5.5% |
| Cost of Revenue | 57M | 5.9% |
| Operating expense | 56M | 8.3% |
| Net Income | -17M | 17.5% |
| EBITDA | -17M | 15.7% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 270M | 6.9% |
| Total Liabilities | 115M | 9.6% |
| Total Equity | 155M | 5% |
| Shares Outstanding | 41M | 3% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -3.4M | 77.9% |
| Cash from investing | -9.7M | 154.5% |
| Cash from financing | 13M | 0% |
EPS
Financial Highlights for Silk Road Medical in Q2 '24
Silk Road Medical reported a revenue of 51M, which is a 9.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 39M, marking a 5.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 57M, a 5.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 56M, showing a 8.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a -17.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -17M, showing a -15.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Silk Road Medical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
